Westlake Longevity Cohort

Recruiting

• Conditions: Aging

• Registration Number: NCT05256251
• Lead Sponsor: Westlake University

Brief Summary

The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians and senior citizens living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. The second aim is to culture the gut microbiota of these elderly people through culturomics. The third aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional/lifestyle recommendation for the public.

Detailed Description

Aging is a major risk factor for most fatal diseases, such as Alzheimer's disease, type 2 diabetes, cardiovascular disease, and cancer. Global population aging is becoming increasingly serious, and this trend is mainly driving the annual increase in the prevalence of aging-related diseases. Healthy longevity is influenced by a variety of factors, such as diet structure, lifestyle, ecological environment, gut microbiome, and genetics. At present, research on healthy longevity is mainly focused on Drosophila, nematodes, and mouse models, but few studies have targeted longevity populations. Centenarians and nonagenarians are the best populations to study healthy longevity. However, the multi-omics molecular characteristics and regulatory mechanisms of healthy longevity in humans are still unclear. Therefore, the We-Longevity design includes centenarians, nonagenarians, and senior citizens. We will determine the fecal/serum metabolome, culturable gut microbiome characteristics, gut microbiome, serum proteome, and genome, together with diet, lifestyle, and disease information.

Study Timeline

• Study Start: 2021-11-15
• Study First Submitted: 2021-11-15
• Study First Submitted QC: 2022-02-21
• Study First Posted: 2022-02-25
• Status Verified: 2025-03
• Last Update Submitted: 2025-06-10
• Last Update Posted: 2025-06-15
• Primary Completion: 2025-11-14
• Study Completion: 2031-11-14

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

• Participants live in Lishui, China.
• Participants intend to remain in Lishui for ≥3 years.

Exclusion Criteria

• Participants with infectious diseases.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Gut microbiome	36 months	Fecal microbiome will be analyzed by 16S/ITS rRNA gene sequencing and metagenome sequencing. Furthermore, fecal microbiota will be cultured, picked and identified.
Physical frailty	36 months	Physical frailty will be evaluated by using Fried's criteria.

Secondary Outcome Measures

Name	Time	Method
Cognitive function	36 months	Cognitive function will be evaluated by using Mini-Mental State Examination (MMSE).
Blood biochemical parameters	36 months	Blood biochemical parameters (e.g., glucose and lipids) will be analyzed by an automated biochemical analyzer.
Metabolomics profiling	36 months	Blood and fecal metabolomics will be analyzed by LC-MS/MS.

Trial Locations

Locations (1)

Lishui Yikang Hospital; 🇨🇳 Lishui, Zhejiang, China